MN-166 (ibudilast) is being developed by MediciNova to treat amyotrophic lateral sclerosis (ALS) and works by suppressing pro-inflammatory cytokines.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
